SCHEMBL30969263

SCHEMBL30969263

NC(=O)c1ccc(OCCN2CCCCC2)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB1 P20618 9/20 0.78
PSMB5 P28074 9/20 0.78
PSMB2 P49721 7/20 0.78
LTA4H P09960 1/20 0.68
KDM4E B2RXH2 3/20 0.65
HRH3 Q9Y5N1 4/20 0.62
CHEK2 O96017 1/20 0.61
KCNH2 Q12809 2/20 0.61
ESR1 P03372 1/20 0.60
ESR2 Q92731 1/20 0.60
MAOB P27338 1/20 0.59
ALDH1A1 P00352 1/20 0.59
LMNA P02545 1/20 0.59
CYP1A2 P05177 1/20 0.59
CHRM2 P08172 1/20 0.59
CHRM4 P08173 1/20 0.59
CHRM5 P08912 1/20 0.59
CYP2D6 P10635 1/20 0.59
THRB P10828 1/20 0.59
CYP2C9 P11712 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3026592 0.98 PSMB1 (0.75) PSMB1PSMB5PSMB2LTA4HKDM4E
SCHEMBL30969243 0.96 PSMB1 (0.72) PSMB1PSMB5PSMB2LTA4HKDM4E
SCHEMBL2002718 0.93 HRH3 (0.72) PSMB1PSMB5PSMB2KDM4EHRH3
SCHEMBL30969209 0.88 HRH3 (0.66) PSMB1PSMB5PSMB2LTA4HKDM4E
SCHEMBL30969213 0.87 DRD3 (0.59) PSMB1PSMB5PSMB2LTA4HKDM4E
SCHEMBL1027972 0.86 PSMB1 (0.80) PSMB1PSMB5PSMB2LTA4HKDM4E
SCHEMBL2741667 0.86 PSMB1 (0.80) PSMB1PSMB5PSMB2LTA4HKDM4E
SCHEMBL6597214 0.86 PSMB1 (0.97) PSMB1PSMB5PSMB2LTA4HKDM4E
SCHEMBL3007594 0.85 GAA (0.71) PSMB1PSMB5PSMB2LTA4HKDM4E
SCHEMBL30969262 0.85 HRH3 (0.65) PSMB1PSMB5PSMB2LTA4HKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4642766-A1 COMPOUNDS AND METHODS FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-11-05 EP disclosed
US-20240246943-A1 MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS University of Florida Research Fooundation, Incorporated (US) 2024-07-25 US disclosed
WO-2024145585-A1 COMPOUNDS AND METHODS FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246943-A1 MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS IL6, IL6ST, IL36G PSMB1 3699/4885PSMB5 3347/4885PSMB2 3041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.